| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23061 |
| Drug | Risankizumab |
| Brand | Skyrizi® |
| Indication | Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
| Assessment Process | |
| Rapid review commissioned | 26/09/2023 |
| Rapid review completed | 07/11/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. April 2024
